NVO241220P111000
- 5.65
- -0.05-0.88%
Novo-Nordisk A/S Newsroom
Why the Investor Craze for Ozempic and Rival Weight-loss Drugs May Resume Next Year
Hims & Hers Initiated at Overweight by Morgan Stanley on Revenue Growth
Denmark has a labor shortage, and the city government can't retain people; is it all Novo-Nordisk A/S's fault?
Novo-Nordisk A/S has increased its number of employees by 75% in less than three years. The expansion of this pharmaceutical giant has led to severe talent competition in Denmark, causing many small businesses to shut down or relocate due to the inability to compete. Some manufacturing companies have moved production outside of Denmark to address labor shortages, and even municipal government employees have left for this pharmaceutical company.
Novo Nordisk's Options Frenzy: What You Need to Know
Is Novo Nordisk A/S (NVO) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Novo Nordisk's Hiring Binge Leaves Danish Firms Starved of Labor
Sector Update: Health Care Stocks Decline Monday Afternoon
Top Midday Stories: Honeywell Mulls Separation of Aerospace Business; Starbucks Expands Parental Leave for US Store Workers
Novo Nordisk's Imminent Capacity Increase Is a Significant Positive -- Market Talk
The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect
Novo Nordisk to Invest $1.2 Billion in New Plant in Denmark
Novo Nordisk Says Catalent Buyout to Close Soon as Regulatory Conditions Met
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
CFRA Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $122
Unusual Options Activity: YMM, SHAK and Others Attract Market Bets, YMM V/OI Ratio Reaches 100.0
Latest research confirms: Novo-Nordisk A/S Ozempic is associated with a rare risk of vision loss.
① A latest study confirms that Ozempic, a star drug from the Danish pharmaceutical giant Novo-Nordisk A/S, is associated with an increased risk of a rare eye disease that leads to vision loss; ② According to an analysis by Nordic researchers of years of patient records from Denmark and Norway, diabetic patients using Ozempic are more than twice as likely to develop NAION compared to patients using another diabetes medication.
Market Whales and Their Recent Bets on NVO Options
Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss.
Express News | Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss
'Ozempic Link to Rare Vision Loss Risk Confirmed in Study; Risk of Eye Condition Remains Low; Patients Should Be Aware; NAION Occurs When Loss of Blood Flow Damages Optic Nerve' - Bloomberg News